Juul to Pay $38 Million in Settlement with Pennsylvania

Dec.13.2022
Juul to Pay $38 Million in Settlement with Pennsylvania
Juul to pay $38 million in settlement with Pennsylvania over deceptive marketing to youth for e-cigarettes.

Juul has agreed to pay $38 million to settle with the state of Pennsylvania, after the attorney general's office accused Juul of deceiving consumers about the safety of its electronic cigarettes for teenagers.


Pennsylvania Attorney General Josh Shapiro filed a lawsuit against Juul in 2020, accusing the e-cigarette manufacturer of targeting young people using marketing strategies similar to tobacco companies and violating the state's Unfair Trade Practices and Consumer Protection Laws.


The announced settlement terms on Monday limit Juul's marketing and advertising practices in Pennsylvania.


Juul is prohibited from selling to minors, posting advertisements within 1,000 feet of schools, and claiming that its products are safer than combustible tobacco products in Pennsylvania. Furthermore, Juul is restricted from selling its products online.


The $38.8 million paid in the settlement agreement will be used by the Pennsylvania Department of Health to fund a project aimed at reducing the harm of litigated charges.


When filing the lawsuit, the Department of Health stated that there have been 61 confirmed cases and 59 suspected cases of e-cigarette product-related lung injuries in Pennsylvania. Over the past 30 days, roughly 13% of students in Pennsylvania have used e-cigarettes, and the settlement is seen as just the beginning of efforts to keep kids safe from the dangers of vaping.


2FIRSTS will continue to cover this topic, with updates available on the 2FIRSTS app. Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT launches two glo HYPER “neo” sticks in South Korea, highlighting tropical flavors
BAT launches two glo HYPER “neo” sticks in South Korea, highlighting tropical flavors
BAT’s heated tobacco brand glo has launched two new products in the HYPER series “neo” sticks — “Island Click” and “Blush Click.”
Aug.18 by 2FIRSTS.ai
U.S. Fifth Circuit Court Rejects Shenzhen IVPS Appeal: Lack of Abuse Liability Research Key to Loss
U.S. Fifth Circuit Court Rejects Shenzhen IVPS Appeal: Lack of Abuse Liability Research Key to Loss
On July 23, 2025, the U.S. Court of Appeals for the Fifth Circuit ruled to reject the petition for judicial review filed by Shenzhen IVPS Technology Co., Ltd. (IVPS) and its U.S. distributor ECIGRUSA (Worldwide Vape Distribution) against the FDA, thereby upholding the FDA’s denial of their Premarket Tobacco Product Applications (PMTAs) for six open-system e-cigarette devices and components. The court held that the lack of key evidence on “abuse liability” alone was sufficient grounds to support
Aug.15 by 2FIRSTS.ai
Reuters: The US FDA, under pressure from the White House, will complete its review of nicotine pouches such as ZYN, VELO, and on! by the end of December
Reuters: The US FDA, under pressure from the White House, will complete its review of nicotine pouches such as ZYN, VELO, and on! by the end of December
The U.S. FDA will launch a pilot program to accelerate reviews of nicotine pouch products from Philip Morris International, Altria, BAT’s Reynolds American, and Turning Point Brands, aiming to complete the process by December 2025. The move, driven by pressure from the Trump administration, seeks to address past multi-year approval delays. Nicotine pouches, the fastest-growing U.S. smoking alternative, are seen as lower-risk but raise youth appeal concerns.
Sep.08
Nepalese Authorities Prosecute E-cigarette Smuggling Ring: Over 310,000 Devices Involved, Facing Fines Exceeding $100 Million
Nepalese Authorities Prosecute E-cigarette Smuggling Ring: Over 310,000 Devices Involved, Facing Fines Exceeding $100 Million
The Department of Revenue Investigation (DRI) of Nepal has filed charges against 12 individuals accused of smuggling more than 310,000 e-cigarettes through fraudulent trade, causing tax losses of around USD 10 million. Prosecutors are seeking fines of nearly NPR 17.5 billion (about USD 100 million) as well as prison sentences. The defendants also face the maximum prison terms under law. The investigation revealed that the group used nearly 100 containers to transport goods and sold the products
Aug.19 by 2FIRSTS.ai
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
The EU’s consultation on the Cardiovascular Health Plan, though not mentioning nicotine, has sparked debate over novel tobacco regulation. Advocates urge evidence-based recognition of harm reduction products, while opponents call for tighter rules. The plan may influence TPD III, drawing close scrutiny from both industry and health groups.
Sep.01
Global Tobacco Control Policy Debate: Medical Experts Call for Science-Based Approach, Promoting Harm Reduction Over Total Bans
Global Tobacco Control Policy Debate: Medical Experts Call for Science-Based Approach, Promoting Harm Reduction Over Total Bans
Health professionals worldwide are urging a shift from abstinence-only tobacco policies toward evidence-based harm reduction. Despite bans, smoking remains prevalent in countries like India, while prohibition fuels black markets in Europe and misinformation among doctors in the U.S. Many argue that regulated alternatives could save lives where cessation fails.
Sep.09